If you want to know who really controls ResMed Inc. (NYSE:RMD), then you'll have to look at the makeup of its share registry. With 73% stake, institutions possess the maximum shares in the company.
We maintain our USD 258 fair value estimate for narrow-moat ResMed RMD, or AUD 40 per CDI at current exchange rates, following first-quarter fiscal 2024 results. Underlying EBIT of USD 319 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results